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Phenotypic plasticity, the ability of cells to reversibly alter their phenotypes
in response to signals, presents a significant clinical challenge to treating
solid tumors. Tumor cells utilize phenotypic plasticity to evade therapies,
metastasize, and colonize distant organs. As a result, phenotypic plasticity
can accelerate tumor progression. A well-studied example of phenotypic
plasticity is the bidirectional conversions among epithelial, mesenchymal,
and hybrid epithelial/mesenchymal (E/M) phenotype(s). These conversions
can alter a repertoire of cellular traits associated with multiple hallmarks
of cancer, such as metabolism, immune evasion, invasion, and metastasis.
To tackle the complexity and heterogeneity of these transitions, mathemati-
cal models have been developed that seek to capture the experimentally
verified molecular mechanisms and act as ‘hypothesis-generating machines’.
Here, we discuss how these quantitative mathematical models have helped
us explain existing experimental data, guided further experiments, and pro-
vided an improved conceptual framework for understanding how multiple
intracellular and extracellular signals can drive E/M plasticity at both the
single-cell and population levels. We also discuss the implications of this
plasticity in driving multiple aggressive facets of tumor progression.
1. Introduction
A remarkable feature that cancer cells use to evade
therapy, metastasize, and drive tumor progression is
phenotypic plasticity, that is, the ability of cells to
switch back and forth among multiple phenotypes in
response to varied internal or external signals (H€olzel
et al., 2012). Phenotypic plasticity is usually tightly
controlled during adult homeostasis. It comes into
play only when needed, such as during tissue repair,
when resident stem cells give rise to cells that need to
be replenished. However, during tumor progression,
many of the molecular brakes against phenotypic plas-
ticity are deregulated, enabling cancer cells to behave
as ‘moving targets’ that can play ‘hide-and-seek’ with
multiple therapeutic regimes (Roesch, 2015; Varga
et al., 2014). In addition, these phenotypic conversions
can facilitate adaptation by enabling genetically identi-
cal cells to exhibit a diverse set of phenotypes and may
also help fuel genetic evolution of cancer cells (Brooks
et al., 2015; Mooney et al., 2016; Yadav et al., 2016).
A canonical example of such phenotypic plasticity
that contributes significantly to both metastasis and
drug resistance is epithelial/mesenchymal (E/M)
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plasticity, that is, the ability of cells to undergo a par-
tial or full epithelial-mesenchymal transition (EMT)
and its reverse mesenchymal-epithelial transition
(MET) (Diepenbruck and Christofori, 2016). Interest-
ingly, emerging evidence strongly suggests that these
transitions are rarely ‘all-or-none’. Rather, cancer cells
can often display a hybrid E/M phenotype by combin-
ing various epithelial and mesenchymal morphological
and/or molecular features (Jolly et al., 2015; Nieto,
2013; Nieto et al., 2016). Cells in this (these) hybrid
state(s) can be much more tumorigenic and drug resis-
tant as compared to those that are more fixed in a
strongly epithelial or mesenchymal state (Biddle et al.,
2016; Grosse-Wilde et al., 2015; Jolly et al., 2015).
Thus, elucidating the underlying principles of these
dynamic transitions is of foundational importance for
countering the yet insuperable clinical aspects of can-
cer – metastasis and drug resistance.
Recent progress in dissecting the molecular mecha-
nisms underlying these phenotypic transitions has
enabled the development of quantitative mathematical
models that can be used as hypothesis-generating tools
to guide further experiments. In this review, we high-
light how an integrative theoretical-experimental
approach has helped us better characterize E/M plas-
ticity. For instance, mathematical models capturing
the dynamics of core EMT signaling network have
predicted that cells can maintain a hybrid E/M pheno-
type stably and that cells with same genetic back-
ground (cell lines) can contain admixtures of epithelial,
hybrid E/M, and mesenchymal subpopulations. These
predictions have been validated by experimental obser-
vations showing different cell lines can contain sub-
populations of different phenotypes in varying ratios.
2. Why develop quantitative
mathematical models?
Quantitative mathematical models offer us a powerful
conceptual framework to elucidate underlying biological
mechanisms and to propose new sets of experiments by
generating falsifiable hypotheses. They can help inter-
pret or explain the existing experimental data, confirm
or reject alternate hypotheses, predict cellular behavior,
and eventually guide further experiments (Mobius and
Laan, 2015). They can decode the emergent dynamics of
various regulatory networks and biological phenomena,
and enable the experimental biologists to think more
quantitatively in terms of regulatory dynamics. Mathe-
matical models can also help unravel the principles that
govern cancer progression, from the molecular scale all
the way to the population level (Anderson and Quar-
anta, 2008). Thus, these models can aid in guiding
optimal treatment modalities and can contribute to
improved risk prognoses (Altrock et al., 2015).
3. What is a quantitative mathematical
model?
A model of any system is a replica that captures the
system’s essential features and can thus be used to pre-
dict how the ‘original’ system would behave in a vari-
ety of conditions. Each model has its own
assumptions, strengths, and limitations and is therefore
suitable to answer a specific set of questions. In biol-
ogy, we often use various preclinical models (e.g., cell
lines, mouse models, patient-derived xenografts) to
investigate different phenomenon relevant to human
biology, with an implicit expectation that lessons
learned in these preclinical models can provide useful
insights into the functioning of the human system.
Broadly speaking, these biological models can be
in vitro or in vivo. Similar to these model systems, a
quantitative mathematical model is an in silico repre-
sentation of the ‘original’ system, where a set of equa-
tions captures the essence of biological phenomenon
through terms representing different objects involved
in a phenomenon and interactions among them that
govern that phenomenon (Fig. 1A). A bidirectional
communication among mathematical and experimental
biologists has been fruitful in teasing out the mecha-
nistic aspects of many biological processes such as tim-
ing and patterning of developmental events (Lewis,
2008; Oates et al., 2009; Shaya and Sprinzak, 2011).
Just like biological models, mathematical models dif-
fer in scope and purpose (Mobius and Laan, 2015).
For instance, different mathematical models developed
to understand E/M plasticity have focused on different
questions: (a) ‘How do a set of transcription factors
and microRNAs (miR) regulate the intracellular
dynamics of a partial or full EMT/MET and modulate
phenotypic heterogeneity in an isogenic population
(Lu et al., 2013; Steinway et al., 2014; Tian et al.,
2013)?’; (b) ‘How does cell–cell communication affect
the spatial arrangement of epithelial, mesenchymal and
hybrid E/M cells (Boareto et al., 2016)?’; and (c) ‘How
do cells alter their morphological and motility traits
during EMT?’ As one may suspect, developing mathe-
matical models to answer each of these questions
requires quite different experimental data. Therefore,
often times the scope of the model is decided by the
data that are available; for example, whether longitudi-
nal data are available either in discrete time points or
in a more continuous fashion, whether data are avail-
able at a population vs. single-cell level, or whether
the available data are merely for altered protein and
740 Molecular Oncology 11 (2017) 739–754 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Mathematical modeling of EMT/MET M. K. Jolly et al.
transcript levels vs. the data also includes morphology
and motility aspects too. In this review, we will focus
on a set of mathematical models that can be compared
extensively against the existing experimental data.
4. How does one develop a
quantitative mathematical model?
As discussed earlier, the first step in developing a
mathematical model entails being clear both about the
biological question that the model should be able to
answer, and the experimental data available with
which to construct, calibrate, and compare the model.
Second, one must realize the implicit assumptions of
different modeling frameworks and decide whether
operating under those assumptions enables a reason-
able replica of the ‘original’ biological system. These
assumptions should always be judged in light of the
question/phenomenon of interest. Third, one should
strive to accurately incorporate multiple key features
of a phenomenon in one’s model. Finally, the model
should be validated by comparing the predictions of
the model in cases where robust experimental data are
available a priori. Subsequent to model validation, one
can generate predictions that can be tested experimen-
tally and confirmed or falsified (Fig. 1B).
Generating falsifiable predictions is the most useful
application of developing mathematical models.
Therefore, simply fitting experimental data to a
model does little to contribute to new knowledge.
Rather, one should seek to ‘stick the model’s neck out
after it is fitted and try to falsify it’ (Gunawardena,
2014) by predicting how the ‘original’ system (often, the
biological model system being studied) would behave
under altered conditions, such as by introducing genetic
mutations or overexpressing a specific gene.
What happens if there is a mismatch between the
prediction of the mathematical model and the experi-
mental results generated? This mismatch can occur
due to multiple reasons, such as (a) underlying
assumptions of the model are not entirely valid; (b)
the model is not robust, that is, relatively small
changes to the model or its parameters dramatically
change the behavior of the model; and/or (c) techni-
cal inaccuracies in running experiments and/or model
simulations. Once the underlying reason(s) is (are)
identified, and predictions of the mathematical model
score well with experimental results, this iterative
cycle can continue to identify the next set of exciting
research directions to be answered using the same or
a different mathematical and/or biological model(s),
as applicable.
A
B
Fig. 1. Introduction to quantitative mathematical models. (A) Similar to biological models (e.g., cell lines, mouse models, and PDXs),
mathematical models can capture certain aspects of tumor progression. Insights gained using both classes of models can be more than
useful than through any one class alone. (B) The process of developing, calibrating, and validating a mathematical model for a specific
biological question. Generating predictions that can guide further experiments is the keystone of this integrative theoretical-experimental
approach. (All images have been taken from Wikimedia commons).
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5. How can epithelial/mesenchymal
plasticity be represented by a set of
mathematical equations?
An exemplary biological phenomenon in which mathe-
matical modeling has helped provide useful biological
insights is that of E/M plasticity. This plasticity arises via
a gene regulatory network that controls reversible
switches between phenotypes, and has implications for
numerous key biological processes in normal and disease
states. For example, in the context of cancer, phenotypic
switching between epithelial and mesenchymal states via
EMT and MET drives cancer progression, metastasis,
and therapy resistance. These epithelial and mesenchy-
mal cells have distinct morphological and molecular fea-
tures. For instance, epithelial cells have E-cadherin
(CDH1) localized at the cell membrane, which con-
tributes to adherens junctions. Conversely, mesenchymal
cells lack E-cadherin and typically have higher levels of
vimentin (VIM), N-cadherin (CDH2), and aSMA
(smooth muscle actin). Thus, EMT and MET typically
involve widespread changes in gene expression, micro-
RNAs, and epigenetic profiles, as well as cytoskeletal
reprogramming (De Craene and Berx, 2013). An under-
standing of the set of molecular players of interest and
the interactions among them can facilitate development
of a mathematical model that can trace these changes
during EMT and MET, and potentially highlight novel
areas of susceptibility to therapeutic targeting.
The first set of mathematical models developed for
EMT/MET focused on a specific question: Can the
underlying EMT/MET regulatory network enable the
existence of a stable hybrid E/M phenotype, and if so,
what is the molecular signature of this hybrid E/M
phenotype (Lu et al., 2013; Tian et al., 2013)? These
efforts at addressing this question modeled the interac-
tions among two sets of microRNAs and two sets of
transcription factors that were reported to govern
EMT/MET in multiple cell lines – miR-34, miR-200,
ZEB, and SNAIL (Bracken et al., 2008; Gregory
et al., 2008; Kim et al., 2011; Park et al., 2008;
Siemens et al., 2011) (Fig. 2A). The models predicted
Fig. 2. Integrated theoretical-experimental framework to understand E/M plasticity. (A) (Top) An EMT regulatory circuit denoting two
transcription factor families –SNAIL and ZEB, and two miR families – miR-34 and miR-200. Transcriptional (denoted by solid lines) and miR-
mediated (denoted by dotted lines) regulations in this circuit can be represented as a set of mathematical equations (middle) that can then
be solved to attain the steady states or phenotypes (shown by red solid dots) and dynamics of this circuit. (B) (middle) Bifurcation diagram
depicting the change in ZEB mRNA levels, and consequently phenotypic switching (shown by black arrows), for varying values of SNAIL.
Solid blue lines depict stable states (phenotypes), and dotted red lines illustrate unstable states. Mesenchymal cells have highest levels of
ZEB mRNA (topmost blue line), followed by hybrid E/M cells (middle blue line) and then epithelial cells (blue line at the bottom). (Top and
bottom) Immunofluorescence staining for CDH1 (red) and VIM (green) in different cancer cell lines reveals the existence of individual
phenotypes or co-existence of more than one phenotypes, as predicted by the mathematical model. Cell lines corresponding to each region
are marked; for instance, H2291 cell populations contain cells staining for either CDH1 or VIM, but not individual cells costaining for CDH1
or VIM; thus, H2291 maps on to the region where cells can adopt either an E or a M state – {E, M}.
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that under certain conditions, a hybrid E/M phenotype
can be stable and that in isogenic populations, multi-
ple phenotypes can co-exist. In other words, a clonal
population may harbor more than one phenotypic
subpopulations, owing to the nonlinear and highly
interconnected feedback loops among a set of core
EMT players (see three solid blue lines in Fig. 2B,
each of which represents a distinct phenotype – E (low
ZEB1), hybrid E/M (medium ZEB1), and M (high
ZEB1) – as illustrated by cartoons drawn alongside).
These predictions were later validated by experiments
demonstrating subpopulations of E, hybrid E/M, and
M phenotypes in varying ratios in cell lines across
multiple cancer types, as assessed by flow cytometry
and immunofluorescence (Andriani et al., 2016;
Grosse-Wilde et al., 2015; Jolly et al., 2016b; Ruscetti
et al., 2016).
Such co-existing phenotypes, as also observed exper-
imentally in H2291 and DU145 cells (Fig. 2B), may
enable dynamic switching among cells in different phe-
notypes (Ruscetti et al., 2016). This heterogeneity does
not eliminate the possibility that under certain scenar-
ios (i.e., in some cell lines), most, if not all, isogenic
cells display the same phenotype. For instance, the
model predicted regions corresponding to solely
epithelial (SNAIL < 180K molecules in Fig. 2B) and
solely mesenchymal (SNAIL > 230K molecules in
Fig. 2B) states, as validated experimentally by H820
and H1792 cells, respectively (Fig. 2B). It should be
noted that the baseline models predicted such homoge-
neous regions only for epithelial and mesenchymal
phenotypes, but not for a hybrid E/M phenotype.
More importantly, these models motivated the inves-
tigation of behavior of a set of non-small-cell lung
cancer (NSCLC) cell lines that were categorized as
‘hybrid’ based on population-based measurements
(Schliekelman et al., 2015). At a single-cell level, these
‘hybrid’ cell lines contained subpopulations of epithe-
lial and mesenchymal cells (H2291; Fig. 2B) and/or
individual cells co-expressing epithelial and mesenchy-
mal markers, such as CDH1 and VIM (H1975).
H1975 cells exhibited a hybrid E/M phenotype at the
single-cell level over multiple passages (Fig. 3A),
strongly suggesting that a hybrid E/M state can be a
stable phenotype (Jolly et al., 2016b). As compared to
epithelial cells (H820) and mesenchymal cells (H1299)
(Schliekelman et al., 2015), H1975 cells also stained
for nuclear ZEB1 (Jia et al., 2017), thus confirming the
prediction made by the mathematical model developed
by Lu et al. (2013) (Fig. 3B).
Observations in H1975 cells serve as a remarkable
example of the power of leveraging an integrated
theoretical-experimental framework. Although the
mathematical models predicted regions where a hybrid
E/M state may exist as a stable phenotype (see solid blue
line corresponding to 200 < ZEB1 mRNA levels < 600
molecules in Fig. 2B), as already noted, a parameter
region enabling a hybrid E/M state alone was not
observed. Consequently, that led to a search for poten-
tial ‘phenotypic stability factors’ (PSFs) – molecular
players that can enable a monostable {E/M} region.
Incorporating two proteins OVOL2 and GRHL2 that
were reported to form mutually inhibitory loops with
ZEB (Cieply et al., 2012, 2013; Roca et al., 2013) – in
the mathematical model – predicted the existence of a
desired {E/M} region (Hong et al., 2015; Jia et al.,
2015; Jolly et al., 2016b) (Fig. 3A). The role of OVOL2
and GRHL2 as PSFs was validated by experiments
showing that knockdown of either of these proteins in
H1975 drove the cells toward a stable hybrid E/M state
to a fully mesenchymal phenotype (Jolly et al., 2016b).
Similar results in developmental EMT contexts
strengthened the notion that these PSFs can act as
‘molecular brakes’ on EMT that can prevent cells ‘that
have gained partial plasticity’ from undergoing a com-
plete EMT (Watanabe et al., 2014; Werner et al., 2013).
Furthermore, the mathematical model suggested that
overexpression of PSFs can drive an MET, a prediction
already verified in breast and prostate cancer cell lines
(Roca et al., 2013; Werner et al., 2013), and kidney cells
(Aue et al., 2015), thereby indicating that such models
can behave as ‘semiquantitative predictive paradigms’
to predict the cellular behavior pertinent to EMT regu-
lation in multiple cell lines.
These mathematical models also proposed certain
network motifs that can be used to identify further
PSFs, one of which is that a potential PSF typically
forms a double negative feedback loop with ZEB
(Jolly et al., 2016b). Given that E-cadherin is a tran-
scriptional target of ZEB, and E-cadherin can seques-
ter b-catenin on the cell membrane, thus inhibiting
transcriptional activation of ZEB via Wnt/b-catenin
pathway (Mooney et al., 2016), E-cadherin and ZEB
seem to repress one another. Thus, E-cadherin can be
thought of as a potential PSF. However, detailed
mechanism-based models need to be constructed to
investigate that possibility comprehensively.
Despite the utility of these models, it is important to
note that we neither claim that these particular models
can accurately predict EMT regulation for all cell lines
nor that they can necessarily predict responses to all
perturbations that can alter EMT status in a given cell
line. For instance, overexpression of GRHL2 did not
drive MET in the RD and 143B human sarcoma cell
lines (Somarelli et al., 2016). Further experiments
indicated that in RD and 143B, GRHL2 coupled to
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miR-200 and ZEB1 in a different topology as com-
pared to that in multiple (adeno)carcinoma cell lines.
Therefore, GRHL2 did not seem to couple with miR-
200/ZEB feedback loop in one of the topologies pro-
posed to identify potential PSFs (Jolly et al., 2016b).
Consistently, in sarcoma cells, GRHL2 had no effect
on ZEB1 levels. Instead, GRHL2-induced changes
were only observed when ZEB1 was knocked down.
These findings led to the development of a revised
mathematical model that captured these newly
revealed interactions. The revised model was able to
reproduce robustly the key features of experiments in
sarcoma cells, such as the synergistic induction of E-
cadherin levels upon overexpression of both GRHL2
and miR-200 (Somarelli et al., 2016), and predicted
how epigenetic regulation of GRHL2 can modulate
MET. Therefore, ‘no one size fits all’; no model –
either biological or mathematical – fits all different
biological contexts; carcinoma cell lines may not be
reliable biological models to understand sarcoma
biology, and similarly, networks that work well for
predicting carcinoma cell line behavior need not be the
same for sarcoma.
Notwithstanding the complexity and heterogeneity
in the gene regulatory networks that drive EMT and
MET in different contexts, mathematical models can
be constructed to help rationalize existing experimental
results and to guide further experiments, by making
certain approximations or estimations about the model
parameters. Each of the mathematical models devel-
oped above has multiple variables – ZEB, miR-200,
GRHL2, etc. – and each variable is represented by an
equation tracing their levels over time. Each equa-
tion has terms representing the innate production and
degradation rates for those species that can be esti-
mated from their half-lives and/or typical number of
molecules in a cell (Milo et al., 2010). Similarly, each
equation contains terms pertaining to regulation of the
respective species by one another, for instance, inhibi-
tion of ZEB by miR-200. The quantitative parameters
Fig. 3. Characterizing a hybrid E/M phenotype. (A) (left) EMT circuit as shown earlier, with GRHL2 being incorporated based on literature
about its interactions with ZEB. (middle) Bifurcation diagram depicting change in the levels of ZEB mRNA as a function of varying SNAIL
levels, corresponding to the circuit diagram shown in left. It illustrates a monostable {E/M} region highlighted by dotted rectangle. (right)
Immunofluorescence images for E-cadherin (red) and VIM (green) in H1975 cells over multiple passages consistently show single-cell co-
expression for both markers. (B) Immunofluorescence images for E-cadherin, ZEB1, and VIM in H820, H1299, and H1975 cells.
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describing these interactions, such as the number of
binding sites and the fold change in levels upon over-
expression or inhibition, can also be gained from
relevant experimental data. For example, whereas
miR-200s can bind up to eight to nine binding sites on
Zeb mRNA and reduces the protein levels by 90%
(Gregory et al., 2011), miR-34 binds to two binding
sites on Snail mRNA and reduces the protein levels
only by 50% (Kim et al., 2011). Upon estimating a
relevant range of parameter variation, the sensitivity
of these mathematical models to different parameters
can be tested. For instance, the range of levels of
SNAIL for which a hybrid E/M phenotype is observed
is largely robust to 20% variation in parameters (Jia
et al., 2015). Thus, one need not know the exact value
of each parameter in the mathematical model for every
cell line. Instead, estimating their typical range from
the experimental data can be a good first approxima-
tion. This approximation is good because it can be
often impossible to perform all experiments to measure
every single parameter for every single-cell line, and
these measurements can themselves be subject to
uncertainty (Azeloglu and Iyengar, 2015; Kirk et al.,
2015).
Deriving mathematical models to represent biologi-
cal systems is rarely straightforward (Kirk et al.,
2015). Thus, a key to justifiably use mathematical
models is to state the assumptions and uncertainty in
the model structure and/or parameters clearly. If one
believes the assumptions of the model, one must also
believe its conclusions (Gunawardena, 2014) – and this
applies to both mathematical and biological models.
For instance, in models of the EMT/MET regulatory
network described above (Lu et al., 2013; Tian et al.,
2013), more than one family member of a protein or
microRNA are lumped into one variable, for the sake
of simplicity. So, an implicit assumption of these
mathematical models is that, for instance, both ZEB1
and ZEB2 – two members of the ZEB family – behave
identically, which need not be true in all contexts. Sim-
ilarly, in the context of biological models, an underly-
ing assumption in in vitro cell culture is that the
observed behavior of cells in a two-dimensional setup
plated on plastic recapitulates the ‘true’ behavior of
cells in vivo.
6. How can mathematical models be
used to study changes in other
cellular traits connected with EMT/
MET?
EMT and MET are considered as the motors of cellu-
lar plasticity due to their coupling with other cellular
traits such as metabolism, tumor-initiating potential,
genome plasticity, drug resistance, immunosuppres-
sion, and cell–cell communication (Brabletz et al.,
2011; Chen et al., 2014; Fischer et al., 2015; Lu et al.,
2014; Mani et al., 2008; Morel et al., 2008; Tripathi
et al., 2016; Wellner et al., 2010; Zheng et al., 2015).
By using mathematical models similar to those
described above, one can investigate the interplay of
EMT/MET with any one or more of these traits.
For instance, mathematical models have helped rec-
oncile apparently contradictory results with regard to
the interplay between EMT/MET and ‘stemness’ or
tumor-initiating potential. Initially, EMT was proposed
to promote a gain of stem-like properties (Mani et al.,
2008; Morel et al., 2008). However, later studies sug-
gested that cells locked in a mesenchymal phenotype
often lose their stem-like traits (Celia-Terrassa et al.,
2012; Tran et al., 2014) and that both epithelial-like and
mesenchymal-like stem-like subpopulations may exist
(Liu et al., 2014) (Fig. 4A, i–iii). To provide a unifying
schema to explain these apparently conflicting results, a
mathematical model was developed to connect core
EMT players, miR-200 and ZEB, with the master regu-
lators of stemness, LIN28 and let-7 (Yang et al., 2010).
This model proposed that cells in a hybrid E/M pheno-
type can be more likely to gain stemness as compared to
those in either a fully epithelial or mesenchymal state
(Jolly et al., 2014) (Fig. 4B, i-ii). Follow-up experiments
in breast cancer cells demonstrated that hybrid E/M
cells – cells co-expressing canonical epithelial and mes-
enchymal genes to a similar level – can form up to 10
times more mammospheres as compared to strongly
epithelial or mesenchymal cells, thus validating the pre-
diction of the model (Grosse-Wilde et al., 2015)
(Fig. 4B, iii). Hybrid E/M cells also drove aggressive
tumor growth in vivo (Goldman et al., 2015). More-
over, enhanced or acquired drug resistance of breast
cancer and oral squamous carcinoma cells in a hybrid
E/M phenotype further substantiate the proposed corre-
lation between a hybrid E/M phenotype and ‘stemness’
(Biddle et al., 2016; Brown et al., 2016; Goldman et al.,
2015). Despite initial promising validations, further
research is needed to evaluate how well the hypothesis
holds that the hybrid E/M state is more stem-like
(Celia-Terrassa and Kang, 2016). Moreover, the posi-
tioning of a ‘stemness window’ need not be fixed mid-
way on the EMT axis, but could instead be much more
dynamic and subtype- and/or patient-specific (Jolly et
al., 2016a).
Similarly, in a study demonstrating that a mesenchy-
mal phenotype correlates with immune evasion via
reduced expression of the immunoproteasome (a prote-
olytic machinery that plays a key role in immunity and
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homeostasis), a mathematical model was developed to
capture an underlying mechanism of immunoprotea-
some regulation that involved STAT3, STAT1, and
miR-200s (Tripathi et al., 2016). The model predicted
that inhibiting the activation of STAT3 can increase
the levels of immunoproteasome subunits PSMB8 and
PSMB9 in mesenchymal NSCLC cell lines. Indeed,
inhibition of STAT3 using rapamycin led to enhanced
levels of PSMB8 and PSMB9 via an activated STAT1
pathway.
Another specific question where mathematical mod-
els may prove to be crucial to decode the underlying
dynamics is the epigenetic reprogramming accompany-
ing EMT/MET (Tam and Weinberg, 2013). The
‘poised’ chromatin state of ZEB1 in which the ZEB1
promoter simultaneously displays epigenetic marks of
both active and repressed chromatin may enhance
cellular plasticity among cancer stem cells (CSCs)
and non-CSCs and consequently spike tumorigenic
potential (Chaffer et al., 2013). Similarly, epigenetic
A i
ii
iii
i
ii
iii
Fig. 4. EMT–stemness interplay. (A) Schematics representing apparently contradictory results on the EMT status of CSCs (left), as shown
by the position of ‘stemness window’ on the ‘EMT axis’ with epithelial (E) and mesenchymal (M) as two ends. (B) (top) A circuit simulated
via mathematical model by Jolly et al. (2014) for decoding EMT–stemness interplay. (middle) Prediction of the mathematical model about
the location of a ‘stemness window’. (bottom) Experiments showing the relative tumor-initiating potential of E, hybrid E/M, and M
subpopulations (modified from Grosse-Wilde et al., 2015). Figure reproduced from Refs. Jolly et al. (2014), Grosse-Wilde et al. (2015).
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differences can modulate MET induction in sarcomas
(Somarelli et al., 2016). Finally, these epigenetic inter-
actions could possibly modulate the transition rates
among epithelial, mesenchymal, and hybrid E/M
phenotypes in specific cell lines by controlling
genome-wide chromatin marks. A quantitative com-
parison of transition rates as measured using various
reporter systems (Somarelli et al., 2013; Toneff et al.,
2016) and those predicted by modeling of the underly-
ing regulatory networks (Li et al., 2016) can bridge
the gaps in our understanding of E/M plasticity. Simi-
larly, existing theoretical frameworks to investigate
epigenetic regulation (Steffen et al., 2012) can be
integrated with mathematical models incorporating
interconversion among CSCs and non-CSCs (Li and
Wang, 2015; Yang et al., 2012; Zhou et al., 2013) and
temporal mapping of epigenetic changes during EMT/
MET (Kao et al., 2016) to identify the epigenetic
marks that can be targeted to constrain cellular plas-
ticity and thus abate metastatic and therapy-resistant
progression.
7. How can mathematical models
connect signaling aspects to cellular
motility associated with EMT/MET?
Altered cellular motility and cellular morphology traits
are considered to be the primary consequence of
EMT/MET. During EMT, cells typically have reduced
adhesion with their neighbors, and migrate collectively
or individually depending on their intercellular adhe-
sion and spatial confinement (Boekhorst et al., 2016).
For instance, during embryonic development, neural
crest cells undergoing a partial or complete EMT can
migrate as either a multicellular stream or individually,
in order to reach distant tissues. Similarly, during gas-
trulation, both these modes of migration are observed
at different spatiotemporal coordinates (Scarpa and
Mayor, 2016). Typically, collective migration is associ-
ated with a partial EMT or hybrid E/M phenotype
(Kuriyama et al., 2014; Sarioglu et al., 2015), whereas
fully mesenchymal cells tend to migrate alone.
Depending on cell–matrix adhesion, the migrating cells
can also reversibly switch to an amoeboid migration
mode, where cells migrate individually and predomi-
nantly via squeezing through the gaps in extracellular
matrix (ECM) (Pankova et al., 2010; Wolf et al.,
2007). Similar to EMT/MET, the choice between mes-
enchymal and amoeboid modalities need not be a bin-
ary process and cells can exhibit signatures of both
mesenchymal and amoeboid motility – lamellipodia
and bleb-like protrusions, respectively (Bergert et al.,
2012; Yoshida and Soldati, 2006). Preliminary
mathematical models of some of the underlying signal-
ing mechanisms governing these transitions have been
developed (Huang et al., 2014, 2015), but a detailed
analysis of how these molecules impinge upon changes
in cytoskeletal reorganization, cell shape, cell–cell
adhesion, cellular contractility, and cell–ECM mechan-
ics and consequently drive different migration modes
remains to be accomplished.
Multiple existing theoretical approaches for cell
motility models focus on these key mechanical aspects.
Most frameworks for single-cell migration have focused
on fish keratocytes (Holmes and Edelstein-Keshet,
2012; Ziebert et al., 2012). For instance, Shao et al.
(2012) illustrate how cell morphology is determined by
collective effects of myosin contraction, actin polymer-
ization, and adhesion site dynamics. This type of
approach could actually make contact with the time-
course data correlating cell shape with EMT states
(Mandal et al., 2016; Sarkar et al., 2016). In contrast
to these single-cell models, other frameworks have con-
centrated on tissue-level dynamics by constructing
models for adhesive cell clusters and monolayers
(Basan et al., 2013; Bi et al., 2016; Harris et al., 2012;
Kabla, 2012; Zimmermann et al., 2016) (Fig. 5A,B). In
addition to actomyosin dynamics, these models can
incorporate intercellular forces, cell density, substrate
properties, and contact inhibition of locomotion (CIL)
– a fundamental feature of collective cell migration that
promotes the formation of protrusions in a direction
away from their contacts with the follower cells,
thereby propelling the migration by leader cells
(Fig. 5C) (Mayor and Etienne-Manneville, 2016). With
an emerging understanding of mechanochemical
coupling regulating the determination of leader and fol-
lower cells (Riahi et al., 2015), the models described
above focusing on tissue dynamics can elucidate how
different signaling aspects crosstalk with cell and tissue
mechanics during collective cell migration.
In terms of its application to cancer, a form of collec-
tive cell migration where multicellular clusters of tumor
cells can bud off the primary lesions and enter circula-
tion, has been observed to be the predominant way of
successful colonization (Aceto et al., 2014; Cheung
et al., 2016). These clusters of circulating tumor cells
(CTCs) retain their epithelial traits, at least partially,
and act as primary harbingers of metastasis (Cheung
and Ewald, 2016; Grigore et al., 2016; Jolly et al.,
2015). Differential gene expression signatures of leader
vs. follower cells in collective migration and invasion
during metastasis has highlighted JAG1 as a key player
(Cheung et al., 2016; Jolly et al., 2017), thereby reminis-
cent of the involvement of Notch signaling in regulating
leader vs. follower phenotypes in multiple contexts of
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collective cell migration (Blanco and Gerhardt, 2013;
Boareto et al., 2015; Riahi et al., 2015).
This connection between Notch signaling and collec-
tive migration motivated a recently developed mathe-
matical model that incorporated the coupling between
the EMT circuit and the Notch signaling pathway based
on existing experimental data (de Antonellis et al., 2011;
Brabletz et al., 2011; Bu et al., 2013; Niessen et al., 2008;
Sahlgren et al., 2008). This model predicted that Notch-
Jagged signaling, but not Notch-Delta signaling, can
enable both increased numbers and spatial proximity of
hybrid E/M cells that, owing to their ability to both
adhere andmigrate, may lead to the formation of clusters
of CTCs (Boareto et al., 2016). This prediction provides
mechanistic insights into why JAG1 may be crucial for
mediating clustered migration (Cheung et al., 2016), and
is consistent with the evidence that JAG1 is related to
drug resistance (Boareto et al., 2016; Guo et al., 2010), if
we refer to the earlier claim that hybrid E/M cells are
more likely to exhibit stemness. Yet, it remains to be rig-
orously and extensively tested experimentally whether
knockdown of JAG1 can reduce the frequency of clus-
tered migration and thereby curtail metastasis.
For a comprehensive characterization of collective
cell migration in cancer, such signaling mechanism-
based models need to be tied to previously described
models of cell motility in multiple ways, for instance,
by incorporating the effect of cellular stress on the
activation of Notch signaling (Riahi et al., 2015); inte-
grating how matrix stiffness can drive EMT through
TWIST1-GP3B2 pathway (Wei et al., 2015); including
how matrix density can alter the levels of membranous
E-cadherin and affect the EMT status of cells (Kumar
et al., 2014); and considering that ZEB1-mediated col-
lagen deposition and stabilization (Peng et al., 2016)
can increase matrix density. Developing such
mechanochemical models can reveal how phenotypic
transitions are coupled to the repertoire of mechanical
signals that cancer cells experience and generate
(Przybyla et al., 2016).
8. What other open questions in the
regulation of EMT/MET can benefit
from mathematical models?
Multiple open questions related to EMT/MET furnish
exciting opportunities for cross-pollination of ideas
among experimental and computational biologists,
including (a) ‘How many intermediate states can cells
attain en route to EMT and MET?’; (b) ‘What is the
A
B
C
Fig. 5. Mathematical models for cell motility. (A) Each cell is represented by two particles, both of which exert forces on the substrate.
Upon cell–cell contact, due to contact inhibition of locomotion, these forces change in magnitude and direction. (reprinted from
Zimmermann et al., 2016) (B) Simulations for individual cell migration (left) and collective cell migration (right); shown is one snapshot
emerging from this model of cell motility. (C) Individual migration observed for mesenchymal cell line H1299 and collective migration with
the emergence of leader cells (highlighted by arrow) forming finger-like projections observed for H1975 (hybrid E/M cell line) – reproduced
from Jolly et al. (2016b). Figure reproduced from Refs. ’Zimmermann et al. (2016), Jolly et al. (2016b)‘.
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genomic, proteomic, and epigenetic signature of these
states?’; (c) ‘How symmetric are the dynamics of EMT
and MET, and do cells display hysteresis (i.e., cellular
memory)?’; and (d) ‘What is the relative stability and
relative ‘stemness’ possessed by each of these states?’
As expected, mathematical models encompassing a lar-
ger number of EMT/MET regulatory players than
considered in the initial models (Lu et al., 2013; Tian
et al., 2013) have suggested multiple intermediate
states (Hong et al., 2015; Huang et al., 2017; Steinway
et al., 2015), but these predictions remain to be experi-
mentally verified, thus providing impetus for many col-
laborative efforts.
Furthermore, E/M plasticity of cancer cells has also
been linked to metabolic shifts (Dong et al., 2013;
Kondaveeti et al., 2015; LeBleu et al., 2014) – another
hallmark of cancer (Hanahan and Weinberg, 2011).
Mathematical models that calculate metabolic fluxes
by considering mass balance of various intracellular
metabolites is a standard technique to analyze meta-
bolic signatures (Markert and Vazquez, 2015). Such
models are being increasingly implemented to quantify
metabolic changes in tumor cells (Achreja et al., 2017).
Constructing mathematical modeling frameworks that
integrate these flux-balance models with models for the
dynamics of signaling networks can help investigate
the coupling of metabolic networks with signaling
pathways that regulate E/M plasticity and stemness
(Menendez and Alarcon, 2014; Peiris-pages et al.,
2016). These new frameworks can offer novel insights
into the emergent consequences of bidirectional cross-
talk among these networks driving these different hall-
marks of cancer.
In addition to discerning this intracellular crosstalk,
mathematical models can infer the dynamics of stro-
mal cells as well as intercellular tumor–stroma signal-
ing and act as in silico coculture systems. For instance,
mechanism-based mathematical models can explain
how macrophages can exhibit an intermediate polar-
ization status between M1 and M2 (Italiani and
Boraschi, 2014). Further, models capturing the cross-
talk between differentially polarized macrophages and
cancer cells (Yang et al., 2016) at an intracellular deci-
sion-making level as well as at a population level (i.e.,
multiscale models) can help visualize how cancer cells
can engineer their microenvironment to their benefit
and drive tumor progression, and hence propose
strategies to restrict it.
9. Conclusion
As discussed above, an integrated theoretical-
experimental approach has been instrumental in
characterizing E/M plasticity and cellular traits associ-
ated with this plasticity. Concomitant with the
renewed understanding that cancer can be viewed as
an ecosystem unto itself (Yang et al., 2014), mathe-
matical models capturing the interplay between tumor
cells and multiple components of the tumor microenvi-
ronment can decode underlying organizing principles
that manifest as myriad phenotypic complexities
(Hanahan and Weinberg, 2011). Therefore, an iterative
crosstalk between theory and experiment can help pro-
pel the hope that cancer biology and treatment ‘will
become a science with a conceptual structure and
logical coherence that rivals that of chemistry or
physics’ (Hanahan and Weinberg, 2000) into reality.
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